NanoTemper Technologies Launches DLS Capability With Prometheus Panta, Bringing High-Resolution, Domain-Specific Stability Characterization to Biologics
24.9.2020 12:48:00 EEST | Business Wire | Press release
NanoTemper Technologies, well-known for creating tools that address challenging characterizations, today introduced Prometheus Panta, a multi-parameter stability characterization instrument. By combining DLS for particle size determination with nanoDSF for thermal unfolding and backreflection for aggregation, researchers in biologics formulation optimization, developability, or comparability assessments will find that Prometheus Panta offers superior characterization of their candidate molecules.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200924005395/en/
(Photo: Business Wire)
“Inevitably, researchers will come across candidate molecules that present challenges. Here’s where Prometheus Panta shines, offering a solution they can rely on for clear, trustworthy, and high-resolution data for colloidal and conformational stability,” said Philipp Baaske, Co-CEO of NanoTemper.
Having the right technology really matters when researchers need to detect small differences or subtleties in unfolding events. Missing these details means handing over subpar candidates to teams working downstream — a costly mistake for drug pipelines.
“For the first time, researchers are able to correlate particle sizing, thermal unfolding and aggregation results collected throughout an entire thermal ramp,” comments Charles Heffern, Product Manager at NanoTemper. “This gives them a completely new perspective about stability attributes at the domain level that they would’ve otherwise missed.” Getting clear answers to questions — Which domains have a tendency to aggregate and at what temperature does this happen? Is the increase in particle size at a certain temperature due to an unfolding event for a particular domain? — are now possible.
Visit nanotempertech.com/prometheus-for-biologics to find out more details. For the most up-to-date information, follow NanoTemper on LinkedIn, Facebook, and Twitter.
About NanoTemper Technologies
Our mission at NanoTemper Technologies is to enable everyone to do science that matters by always pushing the limits. We’re focused on making tools that address challenging characterizations for use in drug discovery and basic science research. Working with scientists striving to make a difference in the world gets us excited. If you’re facing challenges with affinity screening, molecular interactions, protein stability, or protein quality, let’s talk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200924005395/en/
Contact information
Jocelyn Davé
jocelyn.dave@nanotempertech.com
+1-415-316-6313
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Introduces AQUASCENT™: Advanced Water-Based Fragrance Technology30.9.2026 10:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances and health and biosciences, today introduced AQUASCENT™, a new vegan, water-based carrier for fine fragrance. Crafted from a proprietary formula made with biodegradable materials, AQUASCENT™ delivers enhanced olfactive performance and visual clarity for consumers while supporting a more sustainable approach to shipping the product. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929938674/en/ AQUASCENT™ is IFF's new water-based fragrance carrier technology that maintains visual clarity while supporting fragrance loads from 10% to up to 25%, compared with up to 15% for most comparable systems. “AQUASCENT™ reflects our continued investment in new scent technologies and formats that create compelling fragrance experiences while supporting the industry’s growing focus on sustainability,” said Sabrya Meflah, president of Fine Fragrance for IFF Scent. “This technology illus
PREPAR-VIE Selects Clearwater Analytics to Modernize and Replace Its Investment Management System30.9.2026 10:00:00 EEST | Press release
Clearwater Analytics today announced that PREPAR-VIE, a life insurance company managing more than €9 billion in assets, has selected Clearwater as its technology partner to unify its front-to-back investment operations within a single, integrated platform. According to S&P Global Ratings, France is among the key drivers of life insurance growth in Europe, as insurers continue to shift their offerings toward unit-linked products. In this context, the best-positioned players are those with real-time visibility across the entire investment lifecycle. With Clearwater, PREPAR-VIE will simplify its investment operations and streamline reporting for both its general account and its unit-linked investments within a single platform. Clearwater covers the entire investment lifecycle — from portfolio and order management to multi-standard investment accounting (French GAAP and IFRS), reconciliation, and unit-linked fund operations. This modern platform automates tasks across teams and systems to
SES and Sky Sign Multi-Year Satellite Capacity Agreement30.9.2026 09:50:00 EEST | Press release
SES and Sky have extended their long-standing partnership in a new multi-year agreement for direct-to-home (DTH) satellite services across the United Kingdom and Republic of Ireland, running into the next decade. Under the agreement, Sky will continue to leverage SES's satellite capacity at the 28.2 degrees East orbital position to deliver television services to millions of households across the region. The renewal extends a partnership that dates to 1988 and reinforces satellite's ongoing role in delivering premium television experiences at scale. “As we give customers more choice in how they access Sky, satellite continues to play an important role in how we deliver our services to customers across the UK and Ireland,” said Nick Herm, Group Chief Operating Officer, Sky. “This agreement with SES provides the reliability, reach and service quality we need to continue delivering the viewing experience our satellite customers expect.” "Sky has been a valued partner of SES for nearly four
rhode Launches at Sephora in Europe, Marking Its First Retail Presence Across 19 New Markets30.9.2026 09:30:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), is available starting today, Wednesday, 30 September, 2026, at Sephora online and in over 500 stores across Europe. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This follows the 2025 rollout with Sephora in the U.S., Canada, and the U.K. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929500812/en/ rhode launches into Sephora across Europe Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode is the No. 1 overall skincare brand in the U.S. by EMV and continues to deliver significant year-over-year growth, according to CreatorIQ.* rhode is now available for con
EADV 2026: Galderma’s New Data Show Sustained Improvements with Nemluvio ® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis30.9.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nemluvio is well-tolerated and associated with sustained and continuous improvements in skin lesions, itch, sleep disturbance and quality of life in adults and adolescents with moderate-to-severe atopic dermatitis.1 The findings will be shared in an oral presentation, titled ‘Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label extension study in adults and adolescents with moderate-to-severe atopic dermatitis’, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, on Thursday, October 1, from 10:45-10:55 AM CET in Hall N by Dr. Matthias Augustin, an ARCADIA clinical trial investigator. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260929663019/en/ “These three-year data provide important evi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom